美“零和”思维挡不住中国创新药

Core Viewpoint - The U.S. is facing increasing competition in the biopharmaceutical sector, particularly in innovative drugs, leading to proposed high tariffs on imported drugs and copper, with drug tariffs potentially reaching 200% [1] Group 1: U.S. Policy and Competition - The U.S. National Security Council has reported that China is systematically challenging U.S. biotechnology dominance, particularly in antibody-drug conjugates (ADCs), where Chinese companies dominate nearly half of the global research [1][2] - The U.S. decision to impose tariffs is driven by a sense of crisis and insecurity regarding the competitive landscape in biopharmaceuticals [1][3] Group 2: China's Rise in Biopharmaceuticals - Prior to 2010, Chinese pharmaceutical companies were largely invisible in the global innovative drug market, relying heavily on generics, but significant reforms since 2015 have led to a rapid development of an independent innovation system [2][3] - The number of innovative drugs launched in China has surged from 9 in 2018 to an expected 48 by 2024, aided by expedited approval processes [2] Group 3: Collaborative Dynamics and Market Trends - Despite U.S. efforts to limit collaboration with Chinese firms, American pharmaceutical giants are increasingly entering into licensing agreements with Chinese companies, with significant transaction values reported [4][5] - The cost of developing innovative drugs in China is only 20-30% of that in the U.S., with a faster development cycle, highlighting China's competitive edge in the biopharmaceutical sector [4][5] Group 4: Future Outlook and Strategic Implications - The ongoing political tensions are unlikely to disrupt the deepening collaboration between U.S. and Chinese pharmaceutical industries, as mutual dependencies in research and clinical trials persist [5] - The future of innovative drug development may hinge on the ability to create an open and collaborative ecosystem rather than maintaining technological hegemony, suggesting that the U.S. may miss out on future advancements if it continues to pursue isolationist policies [5]